Innovent's CAR-T Therapy Awarded Breakthrough Status in China
February 25, 2021 at 06:18 AM EST
Innovent Biologics of Suzhou and IASO, a Bay Area-Nanjing biopharma, announced their partnered CAR-T candidate was granted Breakthrough Therapy status in China . The BTD designation for CT103A is based on results from an ongoing China Phase I/II trial in patients with relapsed or refractory multiple myeloma. CT103A is a fully-human anti-B-cell maturation antigen targeted CAR-T cell therapy that uses a lentivirus as a gene vector to transfect autologous T cells. More details.... Stock Symbol: (HK: 01801) Share this with colleagues: // //
